semaglutide adverse reactions This figure depicts the common and severe effects associated Comparative safety and side effects

Although semaglutide has not yet been assessed in T1D in clinical trials, retrospective data of off-label use has suggested benefits in reducing HbA1c, weight and insulin requirements 19,20

Incorrect levels of electrolytes can lead to other serious problems, affecting your heart and muscles

Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval

The inclusion of glucagon agonism is why retatrutide produces such dramatically different outcomes in liver fat reduction compared to GLP-1 only compounds